Health Professionals: Public Health Implications of UGT1A1 Genotyping and Use of Irinotecan Chemotherapy for Metastatic Colorectal Cancer
ShareCompartir
This website is archived for historical purposes and is no longer being maintained or updated.
On This Page
This page contains information that is not part of the EGAPP™ recommendation, but may be important for health professionals.
Public Health Implications
Colorectal cancer is the third leading cause of cancer in the United States with an estimated 142,000 new cases and more than 50,000 deaths estimated in 2010.[1]Approximately 15% of cases involve distant metastasis and may be candidates for irinotecan therapy. Public health practitioners may choose to use this EGAPP™ recommendation information to support the following public health activities:
- Assess current usage of genetic tests to determine the need for targeted educational campaigns aimed at informing providers and the public about EGAPP recommendations and limitations of UGT1A1 genotyping.
- Disseminate these Web-based materials and the EGAPP™ recommendation to partners and other groups to increase awareness of these resources.
- Page last reviewed: October 21, 2011 (archived document)
- Content source: